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a b s t r a c t
The regenerating gene, Reg, was originally isolated from a rat regenerating islet cDNA library, and its
human homolog was named REG Iα. Recently, we reported that REG Iα mRNA as well as its product were
overexpressed in ductal epithelial cells in the minor salivary glands of Sjögren's syndrome (SS) patients.
This study was undertaken to elucidate the role of cytokines and the subsequent intracellular
mechanism for induction of REG Iα in the salivary glands of SS patients. We prepared a reporter plasmid
containing REG Iα promoter (1190/þ26) upstream of a luciferase reporter gene. The promoter plasmid
was introduced by lipofection into human NS-SV-DC and rat A5 salivary ductal cells. The cells were
treated with interleukin (IL)-6, IL-8, and a combination of the two. Thereafter transcriptional activity of
REG Iα was measured by luciferase assay. We found that IL-6 stimulation, but not IL-8, signiﬁcantly
enhanced the REG Iα promoter activity in salivary ductal cells. Deletion analysis revealed that the region
of 141 to 117 of the REG Iα gene was responsible for the promoter activation by IL-6, which contains a
consensus sequence for signal transduction and activation of transcription (STAT). The introduction of
siRNA for human STAT3 abolished IL-6-induced REG Iα transcription. These results showed that IL-6
stimulation induced REG Iα transcription through STAT3 activation and binding to the consensus
sequence of REG Iα promoter in salivary ductal cells. This IL-6/STAT dependent REG Iα induction might
play a role in the pathogenesis of SS.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The regenerating gene, Reg, was originally isolated from a rat
regenerating islet cDNA library [1,2]. The Reg and Reg-related
genes were isolated and revealed to constitute a multigene family,
the Reg family, which consists of four subtypes (types I, II, III, and
IV) based on the primary structures of the encoded proteins of the
genes [2,3]. In humans, ﬁve functional REG family genes (REG Iα,
REG Iβ, REG III, HIP/PAP, and REG IV) have been isolated [2,3]. Reg
family gene products act as growth factors and promote cell
proliferation and regeneration; therefore, they are considered to
be important in various inﬂammatory diseases [2,3].
It has been reported that REG family gene expression was
regulated by several cytokines or chemokines, such as interleukin
(IL)-6, IL-8, IL-11, IL-22, interferon (IFN)β, IFNγ, and cytokine-
induced neutrophil chemoattractant-2β [4–10]. IL-6, a pleiotropic
proinﬂammatory cytokine, fulﬁlls its functions by activating Janus
kinase (JAK) and subsequent signal transducer and activator of
transcription (STAT) [11,12]. STAT plays a key role in transmitting
cytokine signals as a transcription factor and in promoting cell
proliferation and anti-apoptosis [13–16]. The involvement of STAT
signaling in the REG gene family expression in gastrointestinal
epithelial cells has also been reported [8,9,17].
Sjögren's syndrome (SS) is a chronic autoimmune disease
characterized by inﬂammation of the salivary and lacrimal glands;
local or systemic overexpression of proinﬂammatory cytokines is
involved in its pathogenesis [11,18–21]. It has been reported that
proinﬂammatory cytokines such as IFNα, IFNγ, tumor necrosis
factor (TNF)α, IL-12 and IL-18, along with other cytokines impor-
tant in T and B cell activation and auto-antibody production, such
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as IL-6 and B cell activating factor (BAFF), are overexpressed in
exocrine glands (such as salivary and lacrimal glands). Recently,
we reported that REG Iα mRNA and its product (REG Iα protein)
were overexpressed in ductal epithelial cells in the minor salivary
glands (MSGs) of SS patients [22]. Furthermore, auto-antibodies
against REG Iα were found in SS patients and the anti-REG Iα auto-
antibody positive patients exhibited signiﬁcantly lower saliva
secretion than the auto-antibody negative patients [22]. We also
showed that the mRNA levels of IL-6 and IL-8 were signiﬁcantly
higher in the SS MSGs than those in normal MSGs [22], suggesting
that those cytokines might be involved in the overexpression of
REG Iα mRNA in the SS MSGs. However, the precise mechanism by
which REG Iα gene activation occurs has been elusive. This study
was undertaken to elucidate the role of cytokines and the
subsequent intracellular mechanism of the induction of REG Iα
mRNA in the salivary ductal cells of SS patients.
2. Materials and methods
2.1. Cell culture
To investigate why/how REG Iα expression is induced in the
salivary duct epithelial cells of SS patients [7], we searched salivary
duct epithelial cells and found two available cell lines: NS-SV-DC
and A5 cells. The NS-SV-DC cells, simian virus 40-immortalized
cells derived from human salivary ducts, were kindly provided by
Dr. M. Azuma (Department of Oral Medicine, Tokushima University
School of Dentistry, Tokushima, Japan) and maintained in Kerati-
nocyte SFM (Life Technologies, Carlsbad, CA) [23]. The A5 cells,
derived from the salivary ducts of male Fischer 344 weanling rats
by treating explanted tissue clumps with 3-methylcholanthrene,
were kindly provided by Dr. B.J. Baum (National Institute of Dental
and Craniofacial Research, NIH, Bethesda, MD) and maintained in
DMEM supplemented with 10% FCS [24,25]. For the stimulation
experiments, the cells were treated with 20 ng/mL human IL-6
(Roche, Mannheim, Germany), 200 ng/mL rat IL-6 (Wako Pure
Chemical, Osaka, Japan), 100 nM IL-8 (Wako Pure Chemical, Osaka,
Japan), 100 nM dexamethasone (Dx; MP Biomedicals, Santa Ana,
CA) or combinations thereof.
2.2. Real-time reverse transcriptase-polymerase chain reaction (RT-
PCR)
Total RNA was isolated from the NS-SV-DC and A5 cells with an
RNAprotect Cell Mini Kit (Qiagen, Hilden, Germany) as described
previously [22,26]. The isolated RNAwas reverse transcribed to the
cDNA using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) for the real-time PCR tem-
plate, as described previously [26,27]. The cDNA was subjected to
PCR with the following primers: β-actin (NM_001101) sense
primer, 5'-GCGAGAAGATGACCCAGA-3' and anti-sense primer, 5'-
CAGAGGCGTACAGGGATA-3'; REG Iα (NM_002909) sense primer 5'-
AGGAGAGTGGCACTGATGACTT-3' and anti-sense primer 5'-TAGGA-
GACCAGGGACCCACTG-3'; STAT3 (NM_213662) sense primer, 5'-
CAGGATGGCCCAATGGAATC-3' and anti-sense primer 5'-CCCAG-
GAGATTATGAAACACC-3'. All the PCR primers were synthesized by
NGRL (Sendai, Japan). Real-time PCR was performed using KAPA
SYBR Fast qPCR Master Mix (Kapa Biosystems, Boston, MA) and a
Thermal Cycler Dice Real Time System (Takara, Otsu, Japan), as
described previously [22,26]. PCR was performed with an initial
step of 3 min at 95 1C followed by 40 cycles of 3 s at 95 1C and 20 s
at 60 1C for β-actin, and 40 cycles of 3 s at 95 1C and 20 s at 64 1C
for REG Iα. The level of REG Iα mRNA level was normalized to the
mRNA level of β-actin as an internal standard.
2.3. Construction of reporter plasmid and luciferase assay
Reporter plasmids were prepared by inserting fragments of
human REG Iα promoter gene (1190/þ26, 508/þ26, -508/
þ26, 468/þ26, 402/þ26, 204/þ26, 141/þ26, and 117/
þ26) into pGL3-Basic vector (Promega, Madison, WI). NS-SV-DC
and A5 cells were seeded in a 24-well plate at 1105 cells per
well, and promoter plasmids were transfected into those cells
using Lipofectamine™ 2000 (Life Technologies) [26,28]. Six hours
after transfection, the medium of each well was replaced with
fresh medium containing various stimulants, such as IL-6 or IL-8,
and incubated for an additional 24 h. The cells were harvested and
extracts were prepared in Extraction Buffer (0.1 M potassium
phosphate, pH 8.8/0.2% Triton X-100; Life Technologies). To moni-
tor transfection efﬁciency, pCMV–SPORT–βgal plasmid (Life Tech-
nologies) was co-transfected in all experiments at a 1:10 dilution.
Luciferase activity was measured using a PicaGene luciferase assay
system (Toyo-ink, Tokyo, Japan) and was normalized by the
β-galactosidase activity as described previously [4,29,30].
2.4. RNA interference (RNAi)
Small interfering RNA (siRNA) directed against human STAT3
was synthesized by NGRL. The sense sequence of siRNA for human
STAT3 was 50-GCACCUUCCUGCUAAGAUUtt-30. The Silencers Select
human scrambled siRNA was purchased from Ambions and used
as a control. The transfection of siRNA into NS-SV-DC cells was
carried out using Lipofectamines RNAiMAX Transfection Reagent
(Life Technologies). The cells were transfected with 5 pmol each of
siRNA in a 24-well culture dish as described previously [31].
2.5. Data analysis
All values were expressed as the mean7SEM. The data were
analyzed by unpaired two-tailed t-test using GraphPad Prism
(GraphPad Software, La Jolla, CA). P value of o0.05 was considered
to be statistically signiﬁcant.
3. Results
3.1. Induction of REG Iα mRNA by IL-6
We reported previously that the mRNA levels of REG Iα, IL-6
and IL-8 in the MSGs of SS patients increased signiﬁcantly [22]. To
investigate whether IL-6 or IL-8 up-regulate REG Iα, we by real-
time RT-PCR to analyze the REG Iα mRNA expression in human NS-
SV-DC salivary ductal cells. Treatment with IL-6 but not IL-8 or Dx,
Fig. 1. The mRNA levels of REG Iα gene in NS-SV-DC human salivary ductal cells
treated with IL-6 (20 ng/mL), Dx (100 nM) or IL-8 (100 nM). The levels of REG Iα
mRNA were measured by real-time RT-PCR using β-actin as an endogenous control.
Data are expressed as mean7SEM of the samples (n¼4). The statistical analyses
were performed using Student's t test.
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induced REG Iα mRNA expression (Fig. 1). The combination of IL-
6þDx or IL-6þ IL-8 had no additional effect compared to IL-6
alone. These results indicate that salivary ductal cells express REG
Iα mRNA in response to IL-6 stimulation.
3.2. Activation of REG Iα gene promoter by IL-6
To determine whether the increase in REG IαmRNAwas caused by
the activation of transcription, a 1216-bp fragment containing 1190-bp
of the promoter region of the human REG Iα gene was fused to the
luciferase gene and transfected into human NS-SV-DC and A5 rat
salivary ductal cells. We found that IL-6 stimulation signiﬁcantly
enhanced REG Iα promoter activity in both the NS-SV-DC and A5 cells.
However, treatment with IL-8 did not change the transcriptional
activity of REG Iα (Fig. 2). These results suggest that REG Iα mRNA
was induced by IL-6 in salivary ductal cells at the transcriptional level.
3.3. Localization of IL-6-responsible region in the REG Iα gene
promoter
In order to identify the region essential for the transcription of
the REG Iα mRNA by IL-6, progressive deletions of the REG Iα
promoter were performed. Down to position 141, the deletions
did not attenuate IL-6-induced REG Iα promoter activity; however,
an additional deletion to 117 caused a remarkable decrease in IL-
6-induced promoter activity of REG Iα (Fig. 3). These results
indicated that the 141 to 117 promoter region of the REG Iα
gene is responsible for REG Iα promoter activation by IL-6.
3.4. STAT3 is a key factor for REG1a gene transcription
A computer-aided search for sequences similar to known cis-
acting elements revealed that the 141 to 117 region of the REG
Iα gene contains consensus binding sequences for STAT. In order to
verify the role of STAT3 in IL-6-induced REG Iα induction, siRNA for
human STAT3 mRNAwas introduced into NS-SV-DC cells, and IL-6-
induced REG Iα mRNA expression was analyzed by real-time RT-
PCR. As shown in Fig. 4, the introduction of siRNA for human STAT3
abolished both IL-6-induced STAT3 up-regulation and IL-6-induced
REG Iα up-regulation.
4. Discussion
In our previous study, we reported that REG Iα protein was
overexpressed in the ductal epithelial cells of MSGs of SS patients,
and that the saliva secretion was attenuated with auto-antibodies
to REG Iα [22]. We also showed that mRNA levels of IL-6 and IL-8
were signiﬁcantly higher in the SS MSGs than in normal MSGs
[22,32]. In the present study we showed that REG Iα overexpres-
sion in salivary ductal cells was induced by IL-6 but not by IL-8 at
the transcriptional level.
IL-6, a potent proinﬂammatory cytokine, is involved in acute
phase response, B cell proliferation and plasma cell formation, and
T cell stimulation and recruitment [11]. High serum concentrations
of IL-6 were found in primary SS (pSS) patients, and the levels of
IL-6 concentration correlated with the degree of lymphocyte
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Fig. 2. Luciferase assays in salivary ductal cells. Human NS-SV-DC cells (A) and rat A5 cells (B) were transfected with constructs containing REG Iα promoter. After
transfection, the cells were stimulated with IL-6 (20 ng/mL human IL-6 in NS-SV-DC cells or 200 ng/mL rat IL-6 in A5 cells) or IL-8 (100 nM human IL-8 in NS-SV-DC cells or
100 nM rat IL-8 in A5 cells); and then the luciferase activities were measured. The diagram represents relative luciferase activities to the untreated group. “Basic” represents a
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Fig. 3. Deletion analysis of REG Iα promoter. Human NS-SV-DC cells (A) and rat A5 cells (B) were transfected with constructs containing various deletion mutants of REG Iα
promoter. Constructs listed on ordinate are numbered according to their 5' terminus in the REG Iα promoter. The transfected cells were stimulated with IL-6 (20 ng/mL
human IL-6 in NS-SV-DC cells or 200 ng/mL rat IL-6 in A5 cells), after which the luciferase activities were measured. The diagram represents relative luciferase activities to
the untreated group of “1190”. All data are represented as the mean7SEM of the samples (n¼34). The statistical analyses were performed using Student's t test against
no addition. nPo0.01 vs no addition.
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inﬁltration in the salivary gland [19,33,34]. Binding of IL-6 to the
receptor leads to homodimerization of IL-6 receptor component
gp130, which results in the activation of JAK and the subsequent
phosphorylation of STAT3 [12]. STAT3 plays a central role in
transmitting cytokine signals to the nucleus and promoting cell
proliferation and anti-apoptosis [13–16]. Thus, the JAK/STAT path-
way has been shown to be involved in carcinogenesis under a
background of inﬂammation. Furthermore, accumulating evidence
indicates that the JAK/STAT pathway might be involved in multiple
immune functions: STAT1 and STAT4 mainly induce IFNγ expres-
sion in Th1 cells, STAT6 induces IL-4 expression in Th2 cells, and
STAT3 induces IL-17 expression in Th17 cells [35].
Our results revealed that IL-6 stimulation enhanced REG Iα
gene expression through STAT3 activation in salivary ductal cells.
The involvement of STAT signaling in REG family gene expression
has been reported by other groups in different cell systems. Lee
et al. reported that the IL-11/STAT3 signaling pathway was
important in Helicobacter pylori CagA-directed REG 3γ (HIP/PAP)
expression in gastric epithelial cells [8]. Sekikawa et al. showed
that REG Iα gene expression was regulated by the IL-22/STAT3
pathway in colon cancer cells and by the IL-6/STAT3 pathway in
gastric cancer cells [9,17]. Most recently, we showed that REG Iα
gene expression was activated in human pancreatic β-cells by the
combined stimulation of IL-6þDx via JAK/STAT3 signaling [36].
These studies were implemented in gastrointestinal cell lines and
pancreatic β-cells, and to the best of our knowledge, this is the ﬁrst
study to report an association between the IL-6/STAT pathway and
REG Iα expression in salivary ductal epithelial cells.
IL-8, also known as CXCL8, is a proinﬂammatory chemokine
associated with the promotion of neutrophil chemotaxis and
degranulation [37]. Several reports have indicated the involvement
of IL-8 in the pathogenesis of SS. Cuello et al. reported that the
MSG ductal epithelial cells of SS patients highly expressed IL-8
[38]. As mentioned above, IL-8 levels were also reported to be
correlated with REG gene expression [7]. In our previous study, we
showed that IL-8 mRNA was highly expressed in SS MSGs [22]. In
the present study, however, we found that IL-8 did not induce REG
Iα expression in salivary ductal cells, suggesting that high levels of
IL-8 in SS MSGs are not involved in REG Iα up-regulation in
the MSGs.
The Reg I gene was originally found to be expressed in rat
regenerating islets, but not in normal pancreatic islets [1]. RINm5F,
a rat insulinoma-derived cell line, displayed a signiﬁcant increase
in cell numbers in the presence of Reg I/REG Iα protein [2,4,26,39].
Human REG Iα protein administration ameliorated diabetes in
NOD mice, with an increase in the β-cell mass [40]. In addition,
anti-REG Iα auto-antibodies, found in the sera of diabetic patients,
retarded the proliferation of pancreatic β-cells in vitro [39]. These
results suggest that Reg I/REG Iα protein stimulates the prolifera-
tion of pancreatic β-cells. We previously reported that pSS patients
with anti-REG antibodies exhibited signiﬁcantly lower salivary
secretion [22], suggesting that IL-6-induced REG Iα protein in
salivary ductal cells is associated with the regeneration of
damaged MSG ductal epithelial cells and that anti-REG auto-
antibodies attenuate the proliferation/regeneration.
In the present study, we showed that the REG Iα gene was
activated by IL-6/STAT3 signaling in salivary duct epithelial cells.
The STAT binding element was reported not only in the REG Iα
promoter but also in other REG family promoters, such as REG Iβ,
HIP/PAP, and REG III promoters [36,41], suggesting possible activa-
tion of the genes in the salivary ducts of SS patients through the IL-
6/STAT3 axis. In our previous study, however, no REG Iβ mRNA was
detected either in either the control or the SS salivary glands. The
mRNA levels of REG III and HIP/PAP were not different between the
control and SS salivary glands. In contrast, REG Iα mRNA levels
were signiﬁcantly higher in the salivary glands of SS patients than
in those of controls [22]. In SS, the involvement of several
cytokines other than IL-6, such as BAFF, IL-12/IL-23, and IFNα,
has also been reported [11]. Combination of these cytokines with
IL-6 might contribute to REG Iα-speciﬁc overexpression in the
salivary duct epithelial cells of SS patients. As a result, anti-REG Iα
auto-antibody levels are elevated in SS patients [22] and salivary
functions might be affected in SS patients.
Xerostomia, which is the chief manifestation of SS, is caused by
salivary gland dysfunction resulting from immune-mediated
inﬂammation. To alleviate xerostomia, treatment with conven-
tional systemic immunosuppressive drugs has been tried as with
other immune-mediated connective tissue diseases; however, the
therapeutic effects were doubtful [42–45]. Recently, treatments
using with monoclonal antibodies that target inﬂammatory cyto-
kines or cell surface antigens were developed to treat several
autoimmune diseases [46]; a monoclonal antibody against the IL-6
receptor exhibited its efﬁcacy in rheumatoid arthritis [47]. As IL-6
has been shown to be highly expressed in the salivary glands of SS
patients, blocking IL-6 and/or its receptor might have beneﬁcial
effects [19]. Our results, however, suggested that IL-6 was asso-
ciated with regeneration of ductal epithelial cells via REG Iα
protein expression. Therefore, blocking IL-6 and/or its receptor
might induce unwanted effects. Several trials have shown that
rituximab, a chimeric anti-CD20 monoclonal antibody that binds
to the B-cell surface antigen CD20, has beneﬁcial effects in treating
xerostomia in SS patients [48,49]. Rituximab therapy has also been
shown to be effective in rheumatoid arthritis, reducing disease
activity and decreasing auto-antibody production [50–52]. It is
possible that the beneﬁcial effects of rituximab in the SS patients
were associated with B-cell depletion and the subsequent
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decrease in the production of pathogenic auto-antibodies, includ-
ing anti-REG Iα auto-antibodies.
In conclusion, the present study showed that REG Iα transcrip-
tion in salivary ductal cells was stimulated by IL-6. Our study also
demonstrated that STAT3 bound the consensus sequence of REG Iα
promoter and regulated transcription in ductal epithelial cells in
response to IL-6 stimulation. It is suggested that overexpression of
REG Iα protein in salivary ductal cells is dependent on the IL-6/
STAT pathway and might play a role in the pathogenesis of SS.
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